Log in or Sign up for Free to view tailored content for your specialty!
Viral Hepatitis News
CDC: Heplisav-B joins recommended HBV vaccine options for pregnant patients
Data from a postlicensure study support the CDC’s recommendation that Heplisav-B can now be administered to pregnant persons needing hepatitis B vaccination, as its use did not appear to increase risk for major birth defects or miscarriage.
HCC incidence nearly 5-times higher among HBV, HDV coinfected patients with cirrhosis
Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.
‘Only one in six’ veterans with chronic HBV finish HDV testing despite severe disease risk
Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.
Log in or Sign up for Free to view tailored content for your specialty!
Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children
SAN DIEGO — Combination therapy with peginterferon alfa-2b and nucleos(t)ide analogues resulted in significantly higher hepatitis B surface antigen loss vs. monotherapy in children with HBV, especially among those aged younger than 7 years.
VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV
SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.
VIDEO: HBsAg loss with tobevibart, elebsiran combination ‘highly promising’ in chronic HBV
SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed.
Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV
SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.
‘Change the HDV narrative’: A call to heighten awareness, prioritize early detection
As you read these words, you may be learning for the first time about hepatitis delta virus — a lesser-known type of hepatitis that is potentially life-threatening.
Anti-HDV positive individuals at ‘significantly higher risk’ for cirrhosis, HCC
Patients who tested positive for hepatitis D virus antibodies were at greater risk for developing hepatocellular carcinoma and other adverse liver-related outcomes, often at a young age, according to study results.
New HCV testing guidelines aim to increase screening among exposed infants
From 2010 to 2020, less than half of perinatally exposed infants were tested for hepatitis C virus, according to a study, but experts are hopeful that new early testing guidelines will ensure more infants are screened and treated.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read